Literature DB >> 7895765

Clozapine is a potent and selective muscarinic M4 receptor agonist.

S H Zorn1, S B Jones, K M Ward, D R Liston.   

Abstract

Clozapine was studied in functional assays at human muscarinic M1-M5 receptors expressed in Chinese hamster ovary cells. Clozapine was a full agonist at the muscarinic M4 receptor (EC50 = 11 nM), producing inhibition of forskolin-stimulated cAMP accumulation. In contrast, clozapine potently antagonized agonist-induced responses at the other four muscarinic receptor subtypes. Selective stimulation of M4 receptors may, in part, explain the hypersalivation observed clinically with clozapine. Moreover, the unique overall muscarinic profile of clozapine may contribute to its atypical antipsychotic efficacy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7895765     DOI: 10.1016/0922-4106(94)90047-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  26 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity.

Authors:  Cyrille Sur; Pierre J Mallorga; Marion Wittmann; Marlene A Jacobson; Danette Pascarella; Jacinta B Williams; Philip E Brandish; Douglas J Pettibone; Edward M Scolnick; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

3.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

Review 5.  Clozapine-induced sialorrhea: pathophysiology and management strategies.

Authors:  Samir Kumar Praharaj; Manu Arora; Sachin Gandotra
Journal:  Psychopharmacology (Berl)       Date:  2006-03-03       Impact factor: 4.530

6.  Quetiapine-induced hypersalivation.

Authors:  Shannon Allen; Zachary Hoffer; Maju Mathews
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 7.  Pharmacological interventions for clozapine-induced hypersalivation.

Authors:  Rebecca Syed; Katie Au; Caroline Cahill; Lorna Duggan; Yanling He; Victor Udu; Jun Xia
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 8.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

9.  Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life.

Authors:  Senan Maher; Aoife Cunningham; Niamh O'Callaghan; Fintan Byrne; Colm Mc Donald; Shane McInerney; Brian Hallahan
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-30

10.  The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Authors:  D M Weiner; H Y Meltzer; I Veinbergs; E M Donohue; T A Spalding; T T Smith; N Mohell; S C Harvey; J Lameh; N Nash; K E Vanover; R Olsson; K Jayathilake; M Lee; A I Levey; U Hacksell; E S Burstein; R E Davis; M R Brann
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.